The goal of this crossover trial is to determine whether the study drug
dehydroepiandrosterone (DHEA) improves right ventricular longitudinal strain measured by
cardiac magnetic resonance imaging at 18 weeks compared to placebo and to assess side effects
and safety in pulmonary arterial hypertension.